Showing 951 results

Filters Content type: News, Editors' picks, About HIV Topic: Side effects

The most common side effects of anti-HIV drugs are short term and are the result of the body getting used to a new drug. Long-term adverse effects and toxicities are less common.

Side effects

Efavirenz Side Effects Include Suicide; It Could Have Been Me

Editor's pick
The Body
31 October 2016
Weight gain & lipodystrophy

The benefit of treatment has outweighed the clinical impact of lipodystrophy, conference hears

News
26 October 2016
Side effects

Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk

News
25 October 2016
Side effects

Doctors in Netherlands observe higher than expected dolutegravir treatment discontinuation rate

News
13 October 2016
Weight gain & lipodystrophy

Two Experts Discuss HIV, Abdominal Fat and Body Shape Changes

Editor's pick
The Body
24 August 2016
Mental & emotional health problems

Efavirenz appears to be associated with elevated suicide risk in START trial

News
10 August 2016
Pharmaceutical industry

Gilead defeats AIDS activists who claimed the company manipulated patents

Editor's pick
STAT
13 July 2016
Side effects

Switching from tenofovir DF to TAF improves bone and kidney safety

News
11 July 2016
Bone & joint problems

Fearing Drugs’ Rare Side Effects, Millions Take Their Chances With Osteoporosis

Editor's pick
New York Times
2 June 2016
Pharmaceutical industry

A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner

Editor's pick
Los Angeles Times
30 May 2016
Side effects

Rare but severe liver side-effects reported among South African patients starting efavirenz-based ART

News
27 May 2016
Starting treatment

In Option B+, side-effects and needing time to think are key reasons for not taking HIV medication

News
19 May 2016
Side effects

START study shows that people starting HIV treatment earlier have better quality of life

News
7 March 2016
New & experimental HIV treatments

TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity

News
25 February 2016
New & experimental HIV treatments

Gilead announces results from first study to evaluate switching to FTAF-based regimens from Truvada® (FTDF)-based regimens

Editor's pick
Gilead press release
24 February 2016
PrEP science

Bone density recovers quickly after stopping PrEP

News
24 February 2016
Bone & joint problems

Tenofovir treatment raises the risk of broken bones

News
23 February 2016
Drug interactions & pharmacokinetics

People taking a large number of non-HIV-related medications more likely to stop or change HIV drugs

News
27 January 2016
Side effects

D:A:D study: long-term treatment with tenofovir associated with increased risk of serious liver disease

News
21 January 2016
Side effects

Viread (Tenofovir, TDF) Linked With Liver Disease and Cancer

Editor's pick
Poz
14 January 2016
PrEP

Short- or Medium-Term PrEP Is Safer Than Aspirin

Editor's pick
AIDSMeds
13 January 2016
PrEP

South African Medicines Agency approves PrEP

Editor's pick
South African MCC
8 December 2015
PrEP

Ipergay PrEP study results published

News
2 December 2015
HIV treatment

Priorities for HIV care: the perspectives of healthcare providers and patients

News
2 November 2015